In Mid Cap -
DII INCREASING, PUBLIC DECREASING
Cash from operating activities is almost DOUBLE π₯
OPM 39%π₯, ROCE 30.4%π₯
Company Fundamentals Details:-
Market Cap 44,419 CR (Mid Cap)
ROCE 30.4% β
, ROE 22.3%β
, D/E 0.02β
,
NPM 28%β
, OPM 39%β
, CURRENT RATIO 5.54β
, PE RATIO 72.9π¨( INDUSTRY 49.3, High in Industry π¨), PEG RATIO 3.48 π¨(3YRS AVG)
GROWTH TTMβ
SALE 15.2% & PROFIT 34.9%
3yrs CAGRβ
SALE 26%, PROFIT 21%
PROFIT FROM OPERATION> NET PROFIT β
CASH FROM OPERATING ACTIVITIES 844.5CR (102.9% OVER LAST YEAR)π₯π₯
PROMOTORS 74.7 (PLEDGE 00)β
FII 1.28%, DII 11.55%
IPO: OFS βΉ33,950 Mn | Listed on BSE & NSE (21 Jul 2025)
Revenue Mix (FY25): Europe 54.6% | North America 26.4% | India 16.6% | Others 2.4%
Client Concentration (FY25): Top 1: 24.2% | Top 2: 22.4% | Top 5: 70.9% (High dependency)π¨π¨π¨
Company Name - Anthem Biosciences Ltd
Don't make investment decisions based on this information, This information is only for educational and informational purposes only.
Before investing plz do your own research, we are not SEBI REGISTERED, not responsible for any profit/loss